Skip to search formSkip to main contentSkip to account menu

vismodegib

Known as: Vismodegibum 
An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ErivedgeGDC-0449

Broader (1)

HhAntag691
NCIt Antineoplastic Agent Terminologyvismodegib 150 MG Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)
Although non-melanoma skin cancers (NMSCs) are associated with a very low mortality risk, they have been reported to have a major… 
2018
2018
Vismodegib treatment in a HIV positive patient on antiretroviral therapy
Observation: We report a case of a 64 year old man presented with a 3 year history of ulcerative basal cell carcinoma involving… 
Highly Cited
2017
Highly Cited
2017
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma
Scientific Reports 7: Article number: 44079; published online: 09 March 2017; updated: 21 April 2017. In this Article, Monika… 
2015
2015
Repurposing mebendazole for the treatment of medulloblastoma.
2015
2015
Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
2015
2015
Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
2015
2015
Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
2013
2013
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer…
4011 Background: The HH pathway is overexpressed in gastroesophageal (GE) tumors. Pre-clinically, HH inhibitors have demonstrated… 
2012
2012
The Zinc Finger Gene ZIC2 Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer
Purpose: Epithelial ovarian tumors (EOT) are among the most lethal of malignancies in women. We have previously identified ZIC2… 
2012
2012
Hedgehog hopes lifted by approval... and stung by failure
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)